Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe
Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe
复制标题
DOI：
10.1684/ejd.2008.0519
复制
发表时间：
2008-11-01
影响因子：
2.5
通讯作者：
Munzel, Ullrich
中科院分区：
文献类型：
--
作者：
Gollnick, Harald;Barona, Carlos Guillen;Munzel, Ullrich
5%咪喹莫特乳膏是一种免疫反应调节剂，批准用于治疗浅表基底细胞癌（sBCC），每日一次，每周5次，持续6周。本报告揭示了5年随访研究的最终结果，以评估咪喹莫特治疗sBCC的复发率。如之前报告的，182例患者入组研究，163例（89.6%）在治疗后12周评估时没有目标sBCC的临床证据;这163例患者接受了Lip随访至5年。在随访期间，18例临床复发发生在靶肿瘤部位，其中8例和10例分别在随访的前6个月和12个月内复发。初始清除患者的持续临床清除率的5年Kaplan-Meier和生命表估计值分别为84.5%和86.9%，考虑组织学因素为90.3%。随访结束时，所有治疗患者的总体治疗成功率估计为77.9%（考虑组织学时为80.9%）。数据支持临床评估初始缓解可预测长期结局。大多数复发发生在早期，这表明在治疗后的第一年内仔细随访很重要。
Imiquimod 5% cream is an immune response modifier approved for the treatment Of superficial basal cell carcinoma (sBCC) once daily, 5 x per week for 6 weeks. This report reveals the final results of 5-year follow-up study to evaluate the recurrence rate of sBCCs treated with imiquimod. As previously reported, 182 patients were enrolled in the Study and 163 (89.6%) had no clinical evidence of their target sBCC at the 12-week post-treatment assessment; these 163 were followed for Lip to 5 years. During the follow-up period, 18 clinical recurrences occurred at the target tumour site, 8 and 10 Of Which Occurred during the first 6 and 12 months of follow-up, respectively. The 5-year Kaplan-Meier and life-table estimates for Sustained clinical clearance of those patients initially cleared were 84.5% and 86.9%, respectively, and 90.3% considering histology. The estimate of overall treatment success for all treated patients at the end Of follow-up was 77.9% (80.9% considering histology). The data support clinical assessment of initial response as predictive of long-term outcome. Most of the recurrences occurred early, indicating that careful follow-up is important during the first year after treatment.